IFNG and hematopoietic and lymphoid cell neoplasm: It is worth noting that in in vitro and in vivo experiments with hematological tumors, blocking IFN-γ signaling can reduce immune checkpoint protein expression and macrophage activation, and does not affect CAR T-cell efficacy but promotes its proliferation, suggesting that blocking IFN-γ in hematological tumors may enhance CAR T-cell function and reduce treatment-related toxicity [55].